|
|
Vaccine Detail
|
Nelipepimut-S Plus GM-CSF Vaccine |
| Vaccine Information |
- Vaccine Name: Nelipepimut-S Plus GM-CSF Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007009
- Type: Multipeptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: ERBB2
- ERBB2
gene engineering:
- Preparation: The vaccine comprised of nelipiminut-S and the hematopoietic growth factor, granulocyte–macrophage colony-stimulating factor (Schneble et al., 2014).
- Description: This is for Breast Cancer (NCT02636582). A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response (Chick et al., 2021; NCIT_C99228).
|
| Host Response |
|
|
| References |
Chick et al., 2021: Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Kemp Bohan PM, McCarthy PM, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips A, Lukas J, Holmes JP, Mittendorf EA, Peoples GE. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clinical immunology (Orlando, Fla.). 2021; 225; 108679. [PubMed: 33485895].
NCIT_C99228: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99228]
NCT02636582: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer [https://clinicaltrials.gov/ct2/show/NCT02636582]
Schneble et al., 2014: Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014; 6(5); 519-531. [PubMed: 24896623].
|
|
